Tricuspid valve regurgitation

Request an Appointment

Stages

After testing confirms a diagnosis of tricuspid or other heart valve disease, your healthcare team may tell you the stage of disease. Staging helps your care team plan the most appropriate treatment.

A grade describes how much blood leaks backward through the valve. The stage of heart valve disease depends on many things, including the grade, along with symptoms, disease severity, the structure of the valve or valves, and blood flow through the heart and lungs.

Heart valve disease is staged into four basic groups:

  • Stage A: At risk. Risk factors for heart valve disease are present.
  • Stage B: Progressive. Valve disease is mild or moderate. There are no heart valve symptoms.
  • Stage C: Asymptomatic severe. There are no heart valve symptoms, but the valve disease is severe.
  • Stage D: Symptomatic severe. Heart valve disease is severe and is causing symptoms.
Request an appointment
Diagnosis & treatmentDoctors & departments
Sept. 23, 2026

Living with tricuspid valve regurgitation?

Connect with others like you for support and answers to your questions in the Heart & Blood Health support group on Mayo Clinic Connect, a patient community.

Heart & Blood Health Discussions

pop77
Living with high calcium score

136 Replies Mon, Oct 12, 2026

teatime
Stopping Carvedilol (Coreg): When will the effects wear off?

419 Replies Sat, Sep 26, 2026

mcphee
High Coronary Calcium Score: How do others feel emotionally?

697 Replies Thu, Sep 17, 2026

See more discussions
  1. Ferri FF. Tricuspid regurgitation. In: Ferri's Clinical Advisor 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 31, 2026.
  2. Otto CM, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021; doi:10.1016/j.jacc.2020.11.018.
  3. Otto CM. Etiology, clinical features, and evaluation of tricuspid regurgitation. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2026.
  4. Phillips KA, et al. Contemporary early postoperative cone repair outcomes for patients with Ebstein anomaly. Mayo Clinic Proceedings. 2023; doi:10.1016/j.mayocp.2022.06.009.
  5. Stress and heart health. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/stress-management/stress-and-heart-health. Accessed May 28, 2026.
  6. Libby P, et al., eds. Tricuspid, pulmonic, and multivalvular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 31, 2026.
  7. Patlolla SH, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation. Journal of the American College of Cardiology. 2022; doi:10.1016/j.jacc.2022.09.045.
  8. Otto CM. Management and prognosis of tricuspid regurgitation. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2026.
  9. Life's essential 8. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8/lifes-essential-8-fact-sheet. Accessed May 28, 2026.
  10. AskMayoExpert. Tricuspid regurgitation (adults). Mayo Clinic; 2025.
  11. Silversides C, et al. Pregnancy and valve disease. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2026.
  12. Edwards EVOQUE Tricuspid Valve Replacement System — P230013. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/recently-approved-devices/edwards-evoque-tricuspid-valve-replacement-system-p230013. Accessed Aug. 28, 2026.
  13. Tricuspid valve repair and tricuspid valve replacement. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/tricuspid-valve-repair-tricuspid-valve-replacement/about/pac-20385087. Accessed Sept. 3, 2026.
  14. Lloyd-Jones DM, et al. Life's essential 8: Updating and enhancing the American Heart Association's construct of cardiovascular health: A presidential advisory from the American Heart Association. Circulation. 2022; doi:10.1161/CIR.0000000000001078.
  15. Wilson WR, et al. Prevention of Viridans group streptococcal infective endocarditis: A scientific statement from the American Heart Association. Circulation. 2021; doi:10.1161/CIR.0000000000000969.
  16. Rehan ST, et al. Transcatheter edge-to-edge repair for tricuspid regurgitation: A systematic review and meta-analysis. Current Problems in Cardiology. 2024; doi:10.1016/j.cpcardiol.2023.102055.
  17. Tang GHL, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. Journal of the American College of Cardiology. 2025; doi:10.1016/j.jacc.2024.10.086.
  18. Heart valve disease. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-valve-disease/diagnosis-treatment/drc-20353732. Accessed May 28, 2026.
  19. Fortier JH, et al. Drug-associated valvular heart diseases and serotonin-related pathways: A meta-analysis. Heart. 2019; doi:10.1136/heartjnl-2018-314403.
  20. Balata M, et al. Comparative analysis of MitraClip/TriClip and PASCAL in transcatheter tricuspid valve repair for tricuspid regurgitation: A systematic review and meta-analysis. BMC Cardiovascular Disorders. 2024; doi:10.1186/s12872-024-04201-6.
  21. Risk factor. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/risk-factor. Accessed May 28, 2026.
  22. O'Gara PT, et al. 10 issues for the clinician in tricuspid regurgitation evaluation and management: 2025 ACC Expert Consensus Decision Pathway. Journal of the American College of Cardiology. 2026; doi:10.1016/j.jacc.2025.07.002.
  23. Mukherjee M, et al. Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2025; doi:10.1016/j.echo.2025.01.006.
  24. Adamo M, et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation: A clinical consensus statement of the Heart Failure Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC. European Journal of Heart Failure. 2024; doi:10.1002/ejhf.3106.
  25. Kucuk HO, et al. Natural history of tricuspid valve regurgitation: Understanding the limitations of medical therapy. Mayo Clinic Proceedings. 2025; doi:10.1016/j.mayocp.2024.09.022.
  26. Arteagoitia Bolumburu A, et al. Determinants of tricuspid regurgitation progression and its implications for adequate management. JACC: Cardiovascular Imaging. 2024; doi:10.1016/j.jcmg.2023.10.006.
  27. Deharo JC, et al. Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: A scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society. Europace. 2025; doi:10.1093/europace/euaf061.
  28. Chick W, et al. A systematic review and meta-analysis of the clinical outcomes of isolated tricuspid valve surgery. American Journal of Cardiology. 2023; doi:10.1016/j.amjcard.2023.07.006.
  29. Kar S, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal randomized controlled trial. Circulation. 2025; doi:10.1161/CIRCULATIONAHA.125.074536.
  30. O'Gara PT, et al. Operator and institutional recommendations and requirements for tricuspid interventions: 2026 ACC/AHA/ASE/HRS/STS expert consensus systems of care document. Journal of the American College of Cardiology. 2026; doi:10.1016/j.jacc.2026.02.5069.
  31. De Backer J, et al. 2025 ESC guidelines for the management of cardiovascular disease and pregnancy. European Heart Journal. 2025; doi:10.1093/eurheartj/ehaf193.
  32. Expert Consensus Panel, et al. The American Association for Thoracic Surgery 2025 expert consensus document: Management of Ebstein anomaly in children and adults. Journal of Thoracic and Cardiovascular Surgery. 2025; doi:10.1016/j.jtcvs.2025.03.014.
  33. 2025 ACC/AHA/HRS/ISACHD/SCAI guideline for the management of adults with congenital heart disease. Circulation. 2026; doi:10.1161/CIR.0000000000001402.
  34. Hammad A, et al. Association between ergot-derived dopamine agonists and valvular heart disease: A systematic review and meta-analysis. Cardiology in Review. 2026; doi:10.1097/CRD.0000000000001387.
  35. TriClip G4 System — P230007. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/recently-approved-devices/triclip-g4-system-p230007. Accessed Aug. 28, 2026.
  36. Medical review (expert opinion). Mayo Clinic. Sept. 16, 2026.

Related

Associated Procedures

Products & Services

Tricuspid valve regurgitation